<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02519062</url>
  </required_header>
  <id_info>
    <org_study_id>1332</org_study_id>
    <nct_id>NCT02519062</nct_id>
  </id_info>
  <brief_title>Role of FDG PET, Immune and Hypoxic Marker in NSCLC</brief_title>
  <official_title>FDG-PET, Marker Immunologici ed Ipossici in Pazienti Affetti da Carcinoma Polmonare Non a Piccole Cellule in Stadio I-III Sottoposti a Chirurgia Radicale</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective study that involves the revision of clinical, instrumental and&#xD;
      pathologic data of an estimated cohort of maximum 130 patients with NSCLC treated with&#xD;
      surgery with radical intent at our center.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective observation that involves the revision of clinical, instrumental and&#xD;
      pathologic data of an estimated cohort of 130 patients with NSCLC treated with surgery with&#xD;
      radical intent at our center.&#xD;
&#xD;
      We will review FDG-PET acquired within 30 days prior to surgery and analyze its principal&#xD;
      imaging characteristics with respect to hypoxic and immune-related markers at&#xD;
      immunohistochemistry (IHC). These markers will be studied on tumor tissue obtained at&#xD;
      surgery, used for diagnostic purposes and stored in paraffin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of SUVmax (Maximal Standardized Uptake Value) in patients with non-small cell lung cancer undergoing surgery with hypoxia expression and tumor immune cell infiltration.</measure>
    <time_frame>Baseline SUVmax up to 1 month before surgery.</time_frame>
  </primary_outcome>
  <enrollment type="Actual">130</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>This is a retrospective study</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor surgical specimen&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        We will recruit a maximum number of 130 NSCLC patients operated radically (stage I-III) at&#xD;
        our institution during 2010-2014, of which are available clinical and instrumental data and&#xD;
        surgical tumor specimen.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of NSCLC (Stage I-III)&#xD;
&#xD;
          -  FDG PET before surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Absence of tumor specimen&#xD;
&#xD;
          -  No clinical data&#xD;
&#xD;
          -  FDG-PET can not be evaluated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Egesta Lopci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Humanitas Clinical and Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Lopci E, Grassi I, Chiti A, Nanni C, Cicoria G, Toschi L, Fonti C, Lodi F, Mattioli S, Fanti S. PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. Am J Nucl Med Mol Imaging. 2014 Jun 7;4(4):365-84. eCollection 2014. Review.</citation>
    <PMID>24982822</PMID>
  </reference>
  <reference>
    <citation>Saintigny P, Burger JA. Recent advances in non-small cell lung cancer biology and clinical management. Discov Med. 2012 Apr;13(71):287-97. Review.</citation>
    <PMID>22541616</PMID>
  </reference>
  <reference>
    <citation>Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007 Jun;26(2):225-39. Review.</citation>
    <PMID>17440684</PMID>
  </reference>
  <reference>
    <citation>Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino GF, Marchetti S, Cortese N, Qehajaj D, Pistillo D, Alloisio M, Roncalli M, Allavena P, Santoro A, Marchesi F, Chiti A. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1954-61. doi: 10.1007/s00259-016-3425-2. Epub 2016 Jun 1.</citation>
    <PMID>27251642</PMID>
  </reference>
  <reference>
    <citation>Castello A, Grizzi F, Toschi L, Rossi S, Rahal D, Marchesi F, Russo C, Finocchiaro G, Lopci E. Tumor heterogeneity, hypoxia, and immune markers in surgically resected non-small-cell lung cancer. Nucl Med Commun. 2018 Jul;39(7):636-644. doi: 10.1097/MNM.0000000000000832.</citation>
    <PMID>29608508</PMID>
  </reference>
  <reference>
    <citation>Grizzi F, Castello A, Qehajaj D, Toschi L, Rossi S, Pistillo D, Paleari V, Veronesi G, Novellis P, Monterisi S, Mineri R, Rahal D, Lopci E. Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer. Cancer Immunol Immunother. 2019 Sep;68(9):1537-1545. doi: 10.1007/s00262-019-02387-9. Epub 2019 Sep 3.</citation>
    <PMID>31482306</PMID>
  </reference>
  <reference>
    <citation>Grizzi F, Castello A, Qehajaj D, Russo C, Lopci E. The Complexity and Fractal Geometry of Nuclear Medicine Images. Mol Imaging Biol. 2019 Jun;21(3):401-409. doi: 10.1007/s11307-018-1236-5. Review.</citation>
    <PMID>30003453</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 26, 2015</study_first_submitted>
  <study_first_submitted_qc>August 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2015</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carcinoma</keyword>
  <keyword>Non-Small-Cell Lung</keyword>
  <keyword>FDG PET</keyword>
  <keyword>hypoxia markers</keyword>
  <keyword>immune markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

